Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages.

Endocrinology | 2016

Macrophage mineralocorticoid receptor (MR) signaling is an important mediator of cardiac tissue inflammation and fibrosis. The goal of the present study was to determine the cellular mechanisms of MR signaling in macrophages that promote cardiac tissue injury and remodeling. We sought to identify specific markers of MR signaling in isolated tissue macrophages (cardiac, aortic) vs splenic mononuclear cells from wild-type and myeloid MR-null mice given vehicle/salt or deoxycorticosterone (DOC)/salt for 8 weeks. Cardiac tissue fibrosis in response to 8 weeks of DOC/salt treatment was found in the hearts from wild-type but not myeloid MR-null mice. This was associated with an increased expression of the profibrotic markers TGF-β1 and matrix metalloproteinase-12 and type 1 inflammatory markers TNFα and chemokine (C-X-C motif) ligand-9 in cardiac macrophages. Differential expression of immunomodulatory M2-like markers (eg, arginase-1, macrophage scavenger receptor 1) was dependent on the tissue location of wild-type and MR-null macrophages. Finally, intact MR signaling is required for the phosphorylation of c-Jun NH2-terminal kinase in response to a proinflammatory stimulus in bone marrow monocytes/macrophages in culture. These data suggest that the activation of the c-Jun NH2-terminal kinase pathway in macrophages after a tissue injury and inflammatory stimuli in the DOC/salt model is MR dependent and regulates the transcription of downstream profibrotic factors, which may represent potential therapeutic targets in heart failure patients.

Pubmed ID: 27253999 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


CD3e (antibody)

RRID:AB_11153307

This monoclonal targets CD3e

View all literature mentions

SAPK/JNK Antibody (antibody)

RRID:AB_2250373

This polyclonal targets SAPK/JNK

View all literature mentions

p44/42 MAPK (Erk1/2) Antibody (antibody)

RRID:AB_330744

This polyclonal targets p44/42 MAPK (Erk1/2)

View all literature mentions

Phospho-p38 MAPK (Thr180/Tyr182) Antibody (antibody)

RRID:AB_331641

This polyclonal targets p38 MAPK, phospho (Thr180 / Tyr182)

View all literature mentions

Phospho-SAPK/JNK (Thr183/Tyr185) Antibody (antibody)

RRID:AB_331659

This polyclonal targets Phospho-SAPK/JNK (Thr183/Tyr185)

View all literature mentions

CD45 (antibody)

RRID:AB_398672

This monoclonal targets CD45

View all literature mentions

Phospho-I B (Ser32) (14D4) Rabbit mAb (antibody)

RRID:AB_561111

This monoclonal targets Phospho-I B (Ser32)

View all literature mentions